News

Velicept Therapeutics announced that its next generation beta-3 adrenoceptor agonist solabegron met the primary endpoint in VEL-2002, a Phase 2b study in patients with overactive…
Read More...

StrideBio announced the signing of a collaboration and license agreement with Takeda Pharmaceutical Company Limited (Takeda) to develop in vivo AAV based therapies for Friedreich's…
Read More...

Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma L.P., in conjunction with Mundipharma EDO GmbH, announced that the U.S.…
Read More...

Elicio Therapeutics, a next generation immuno-oncology company, engineering therapies for cancer killing immune responses, launched and announced the appointment of Robert Connelly as…
Read More...

OWC Pharmaceutical Research Corp., the company transforming cannabis into scientifically proven and clinically approved medical solutions, announces an agreement with the Tel Aviv…
Read More...

Cook Regentec announced the launch of the ProFusion Therapeutic Infusion Needle used for intramuscular or subdermal infusion of therapeutic agents. The device is now available in the…
Read More...

BioInvent International AB, a biotech company focused on the discovery and development of novel immuno-regulatory antibodies to treat cancer and Transgene, a biotech company that…
Read More...

Vect-Horus S.A.S. (Marseille, France) announced that Vect-Horus and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a collaboration and license agreement, focused on the development…
Read More...

The Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency has, by consensus, adopted a positive opinion recommending marketing authorisation for…
Read More...

CytoDyn Inc. announced that new data shows that a weekly dose of 525 mg and 700 mg of leronlimab yielded approximately a 90% response rate for those HIV-infected patients who pass the…
Read More...

Purdue Pharma L.P. announced that it has entered into a landmark agreement with the state of Oklahoma that will establish a National Center for Addiction Studies and Treatment at…
Read More...

AbbVie announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved SKYRIZI (risankizumab), an interleukin-23 (IL-23) inhibitor, for the treatment of plaque…
Read More...

RegeneRx Biopharmaceuticals, a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee's Pharmaceutical Holdings Limited, a Hong…
Read More...

Eli Lilly and Company and ImmuNext announced a global licensing and research collaboration focused on the study of a preclinical novel target that could lead to potential new medicines…
Read More...

The European Commission (EC) has approved Forxiga (dapagliflozin) for use in type-1 diabetes (T1D) as an adjunct to insulin in patients with a BMI ≥ 27 kg/m2, when insulin alone does…
Read More...

Aimmune Therapeutics announced that its phase 3 European clinical trial of AR101 for the treatment of peanut allergy, known as ARTEMIS (AR101 Trial in Europe Measuring oral…
Read More...

MilliporeSigma officially opened its new M Lab Collaboration Center in Molsheim, France. The center is MilliporeSigma's first in Europe and ninth worldwide, providing biopharmaceutical…
Read More...

GlaxoSmithKline plc announced further positive data from the DREAMM-1 study of patients with relapsed/refractory multiple myeloma who received GSK2857916, an investigational anti-B-cell…
Read More...

PARIS & Vivet Therapeutics and Pfizer announced that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer and…
Read More...

Conatus Pharmaceuticals Inc. announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and…
Read More...